in force 2020-04-24 DEFERRED+5 −5§
Amended by Regulation (EU) 2020/561 32020R0561
applies from: 2021-05-26
dates added to the text: 2021-05-26 · dates removed: 2020-05-26
In Section 5.1(h), the date by which the Commission is to provide guidance for expert panels on interpreting the criteria in point (c) was changed from 26 May 2020 to 26 May 2021.
Cited: Annex IX, v2
text before / after
02017R0745-20170505 → 02017R0745-20200424
ANNEX IX
CONFORMITY ASSESSMENT BASED ON A QUALITY MANAGEMENT SYSTEM AND ON ASSESSMENT OF TECHNICAL DOCUMENTATION
CHAPTER I
QUALITY MANAGEMENT SYSTEM
1. The manufacturer shall establish, document and implement a quality management system as described in Article 10(9) and maintain its effectiveness throughout the … 3,623 unchanged words … justification provided by the notified body publicly available via Eudamed.
(h) The Commission, after consultation with the Member States and relevant scientific experts shall provide guidance for expert panels for consistent interpretation of the criteria in point (c) before 26 May 2020. 2021.
5.2. Procedure in the case of devices incorporating a medicinal substance
(a) Where a device incorporates, as an integral part, a substance which, if used separately, may be considered to be a medicinal product within the meaning of point 2 of … 1,770 unchanged words … kept at the disposal of competent authorities for the period indicated in that Section in case a manufacturer, or its authorised representative, established within its territory goes bankrupt or ceases its business activity prior to the end of that period.